A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

Principal Investigator

Dr Joe Browning

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1011991